LayerBio, Inc.

LayerBio, Inc. is a United States-based biotechnology company focused on ophthalmology. According to its official website, the company is developing novel therapies to address unmet needs in the field of ophthalmology. Its lead technology, OcuRing, is described as a novel bioerodible sustained-release drug delivery technology designed for use with any standard intraocular lens (IOL) during cataract surgery. The company is headquartered in Lexington, United States, according to Wikidata. LayerBio operates in the biotechnology and pharmaceutical life sciences sector, with a specific focus on ophthalmic drug delivery. The company's approach centers on combining drug delivery with existing surgical procedures, such as cataract surgery, to provide sustained release of therapeutic agents. Its OcuRing technology is intended to be compatible with standard intraocular lenses, potentially offering a platform approach to treating ocular conditions. As a private company, LayerBio's ownership and financial details are not publicly disclosed in the available evidence. The company's website emphasizes its mission to improve vision and address unmet medical needs in ophthalmology.

LayerBio, Inc. is a biotechnology company based in Lexington, United States, according to Wikidata. The company is developing novel therapies to address unmet needs in ophthalmology, as stated on its official website. Its primary technology, OcuRing, is a bioerodible sustained-release drug delivery system designed for use with any standard intraocular lens (IOL) in cataract surgery. The company's history is not extensively documented in the available evidence, but its focus on ophthalmic drug delivery positions it within the broader biotechnology and pharmaceutical life sciences sector. LayerBio appears to be a private company, with no public listing or major ownership details disclosed in the provided sources. The company continues to develop its OcuRing platform, which aims to provide sustained drug release following cataract surgery, potentially improving outcomes for patients with ocular conditions.

Developer of novel ophthalmic therapies with a focus on sustained-release drug delivery for cataract surgery.

• OcuRing

  A novel bioerodible sustained-release drug delivery technology for use with any standard intraocular lens (IOL) in cataract surgery.

1. 1LayerBiolayerbio.com
2. 2LayerBio, Inc. (United States) - Wikidatawikidata.org